Optimus Healthcare Services, Inc.

Optimus Healthcare Services, Inc., through its subsidiaries, provides community-based oncology practices with the necessary infrastructure and support to enroll their patients on clinical trials. It contracts with pharmaceutical companies or contract research organizations to conduct clinical trials (Phases I-IV) for investigational new drugs, biologics, and medical devices. The company also operates telehealth and compliance technology software-as-a-service platform focuses on creating a personalized pathway to support interventions for chronic care patients suffering from opioid and other substance use disorders, as well as those patients treated for pain management. Optimus Healthcare Services, Inc. is based in Westbury, New York.

Optimus Healthcare Services, Inc. trades as OHCS on OTC. The company is classified in Financial Services / Shell Companies and reports in USD.

The current profile places the business in Shell Companies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $1.50M of revenue and -$11.10M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Optimus Healthcare Services, Inc. can be compared against peers such as American Leisure Holdings, Inc., Alpha Wastewater, Inc., CGS International, Inc., Ecrid, Inc., IFAN Financial, Inc., IGS Capital Group Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $25,009, beta of 0.14, and return on equity of +155.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

OHCS currently shows total debt of $6.01M and beta of 0.14. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 8-K (2025-09-11 00:00:00), 8-K (2025-06-09 00:00:00), NT 10-Q (2025-05-15 00:00:00), 8-K (2025-04-16 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.optimushealthcare.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.